Home › Research › Treatments
Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease
Rolinski M, Fox C, Maidment I, McShane R.. The Cochrane database of systematic reviews, 2012-03-14
Topic: Brain proteins, microglia and lab models
Plain-language summary
Background Previous Cochrane reviews have considered the use of cholinesterase inhibitors in both Parkinson's disease with dementia (PDD) and dementia with Lewy bodies (DLB). The clinical features of DLB and PDD have much in common and are distinguished primarily on the basis of whether or not parkinsonism precedes dementia by more than a year. Patients with both conditions have particularly severe deficits in cortical levels of the neurotransmitter acetylcholine.
What this study adds
Evidence grade: High
This is a pooled review of 1,236 participants. This review assessed cholinesterase inhibitors in dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease, based on the idea that these conditions involve severe loss of acetylcholine. It concerns symptom treatment in these related conditions, not curing or preventing Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Rolinski, M., Fox, C., Maidment, I., & McShane, R. (2012). Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. The Cochrane database of systematic reviews. https://doi.org/10.1002/14651858.cd006504.pub2
Vancouver
Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. The Cochrane database of systematic reviews. 2012. doi:10.1002/14651858.cd006504.pub2. PMID: 22419314.
BibTeX
@article{rolinski2012-22419314,
author = {Rolinski, M. and Fox, C. and Maidment, I. and McShane, R.},
title = {{Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease}},
journal = {The Cochrane database of systematic reviews},
year = {2012},
doi = {10.1002/14651858.cd006504.pub2},
pmid = {22419314},
url = {https://doi.org/10.1002/14651858.cd006504.pub2}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- The clinical features of DLB and PDD have much in common and are distinguished primarily on the basis of whether or not parkinsonism precedes dementia by more than a year.
- Patients with both conditions have particularly severe deficits in cortical levels of the neurotransmitter acetylcholine.
- Therefore, blocking its breakdown using cholinesterase inhibitors may lead to clinical improvement.
- Objectives To assess the efficacy, safety and tolerability of cholinesterase inhibitors in dementia with Lewy bodies (DLB), Parkinson's disease with dementia (PDD), and cognitive impairment in Parkinson's disease falling short of dementia (CIND-PD) (considered as separate phenomena and also grouped together as Lewy body disease).
Why it matters
This review assessed cholinesterase inhibitors in dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease, based on the idea that these conditions involve severe loss of acetylcholine. It concerns symptom treatment in these related conditions, not curing or preventing Alzheimer's disease.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants1,236
- Evidence strengthHigh
How this study scored 74/100
Published in a leading specialty journal, and it is a meta-analysis pooling many studies. Scored zero for effect reported because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (The Cochrane database of systematic reviews) |
| Journal's citation record | 3 / 4 | Cochrane Database of Systematic Reviews: journal h-index 468 (OpenAlex, 2026-10-29) |
| Study design | 12 / 12 | A meta-analysis pooling many studies (from PubMed type “Meta-Analysis”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2012 — within 20 year(s) of the newest study here |
| Sample size | 3 / 4 | 1,236 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | 6 / 7 | Cited 419 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 26.2 citations a year over 16 year(s) since 2012 |
| Impact for its field and year | 5 / 6 | Cited 26.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 13 other studies in this library |
| Still being cited | 2 / 4 | Cited 44 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Rupert H. McShane: h-index 45 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of Oxford: institution h-index 2,205 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 22419314) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 74 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1002/14651858.cd006504.pub2
- PubMed: 22419314
- Original source →
- Free full text: Cochrane Database of Systematic Reviews →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 20.
Later studies that cite this one
13 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.